Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Theodore F, Logan"'
Autor:
Shilpa Gupta, Monika Joshi, James K. Schwarz, Joshua M. Lang, Arkadiusz Z. Dudek, Ajjai Alva, Yousef Zakharia, Li C Liu, Anas Al-Janadi, Eric A. Singer, Theodore F. Logan
Publikováno v:
Journal of Clinical Oncology
PURPOSE We hypothesized that bevacizumab will potentiate activity of pembrolizumab. We conducted a phase Ib/II, single-arm, multisite clinical trial of the combination in metastatic renal cell carcinoma (RCC). PATIENTS AND METHODS Patients with metas
Autor:
Joel Picus, Robert Jones, Susan Halabi, Samuel Broderick, Daniel J. George, Sadie Oberg, Andrew J. Armstrong, Christine M. Lusk, John D. Hainsworth, Ulka N. Vaishampayan, Jorge A. Garcia, Christopher W. Ryan, Theodore F. Logan, Tim Eisen, Walter M. Stadler, Robert E. Hawkins, Igor Puzanov, Lisa Pickering, Andrew Protheroe, Christian K. Kollmannsberger
Publikováno v:
The Lancet Oncology. 17:378-388
Summary Background Non-clear cell renal cell carcinomas are histologically and genetically diverse kidney cancers with variable prognoses, and their optimum initial treatment is unknown. We aimed to compare the mTOR inhibitor everolimus and the VEGF
Autor:
Karl D. Lewis, Thomas Olencki, Thomas W. Flaig, Anthony Jarkowski, Dexiang Gao, Bruce G. Redman, Theodore F. Logan, Marcus Bolden, Elaine T. Lam, Neeraj Agarwal, Timothy M. Kuzel, Arun Sendilnathan, Paul Monk, Jamie Poust, Michael K.K. Wong
Publikováno v:
Journal of Immunotherapy (Hagerstown, Md. : 1997)
Although tyrosine kinase inhibitors (TKI) are the most common first-line therapy for metastatic renal cell carcinoma, high-dose interleukin-2 (HD-IL2) remains the only agent that provides durable complete responses. The optimal sequence of these agen
Autor:
Mizue Krygowski, J. P. Maroto, Charles S. White, Theodore F. Logan, Ignacio Duran, Gary R. Hudes, Mark Shapiro, Anna Berkenblit, Maria Cincotta, Janice P. Dutcher
Publikováno v:
JOURNAL OF CLINICAL ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Purpose Pneumonitis has occurred in patients treated with inhibitors of the mammalian target of rapamycin (mTOR). In a phase III study of patients with previously untreated, poor-prognosis, advanced renal cell carcinoma (ARCC), the mTOR inhibitor tem
Autor:
Jamie Arnott, Jens C. Eickhoff, Michael A. Carducci, Anthony M. Treston, Justine Yang Bruce, George Wilding, Roberto Pili, Glenn Liu, Theodore F. Logan
Publikováno v:
Investigational New Drugs. 30:794-802
Background Current treatment for metastatic renal cell cancer with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKI) have provided improved overall survival, but complete responses are rare. We conducted a multicenter phase I
Autor:
David F. McDermott, Jessica Mehrabi, Janice P. Dutcher, Theodore F. Logan, Walter J. Urba, Ann M. Lau, Jeffrey A. Sosman, Joseph I. Clark, Michael B. Atkins, Marc S. Ernstoff, Kim Margolin
Publikováno v:
Journal of Immunotherapy. 30:839-846
A phase I/II trial was undertaken to determine the maximum tolerated dose of polyethylene glycol interferon-α-2b (PEG-IFN) with interleukin-2 (IL-2), and to evaluate the efficacy and toxicity in patients with metastatic renal cell carcinoma. Patient
Autor:
Charles A. Linker, Robert C. Barrier, David Avigan, Theodore F. Logan, Susan Halabi, Philip L. McCarthy, Kim Margolin, Brian I. Rini, Walter M. Stadler, Eric J. Small
Publikováno v:
Biology of Blood and Marrow Transplantation. 12:778-785
A graft-versus-tumor effect through nonmyeloablative allogeneic stem cell transplantation (N-SCT) in metastatic renal cell carcinoma (RCC) has been reported. An Intergroup phase II trial was undertaken to define further the feasibility, toxicity and
Autor:
Bruce G. Redman, Elizabeth R. Plimack, Ulka N. Vaishampayan, Theodore F. Logan, Kim Margolin, David F. McDermott, Timothy M. Kuzel, Michael R. Harrison, Robert J. Motzer, Hans J. Hammers, Ian M. Waxman, Brian I. Rini, Alexandre Lambert, Saby George, Harry A. Drabkin
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(13)
Purpose Nivolumab is a fully human immunoglobulin G4 programmed death–1 immune checkpoint inhibitor antibody that restores T-cell immune activity. This phase II trial assessed the antitumor activity, dose-response relationship, and safety of nivolu
Autor:
Alexandra S. Bailey, Jeffrey A. Sosman, Su Chun Cheng, Bradley C. Leibovich, Michael Ka Keu Wong, Rupal S. Bhatt, Eugene D. Kwon, Leslie Oleksowicz, Joseph I. Clark, Leonard Joseph Appleman, Sabina Signoretti, Robert A. Figlin, Marc S. Ernstoff, David F. McDermott, Ulka N. Vaishampayan, Nikhil I. Khushalani, James W. Mier, Kim Margolin, Brendan D. Curti, Theodore F. Logan, David J. Panka, Allan J. Pantuck, Janice P. Dutcher, Fairooz F. Kabbinavar, Michael B. Atkins, Arie S. Belldegrun, Meredith M. Regan
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 21, iss 3
Purpose: High-dose aldesleukin (HD IL2) received FDA approval for the treatment of metastatic renal cell carcinoma (MRCC) in 1992, producing a 14% objective response rate (ORR) and durable remissions. Retrospective studies suggested that clinical and
Autor:
Richard Bihrle, Theodore F. Logan, Michael O. Koch, Ashraf A. Mosharafa, Arieh L. Shalhav, Thomas A. Gardner, Richard S. Foster
Publikováno v:
Urology. 62:636-640
Objectives To report on the short-term morbidity of radical nephrectomy in 32 patients with poorer performance status and more advanced primary renal cell carcinoma (RCC). Nephrectomy followed by immunotherapy has been shown to improve survival in se